Patents Examined by San-ming Hui
  • Patent number: 10029991
    Abstract: One aspect of the disclosure relates to derivatives of aryl and heterocyclic ureido aryl and heterocyclic carboxamido isobutyric acids, dichlorophenyl urea, curcumin, and 1,3-diazetidine-2,4-dione, and pharmaceutical compositions thereof. The derivatives disclosed herein can modulate development of adipocytes and various cancer cells, including resistant cancer cells and cancer stem cells. Another aspect of the disclosure relates to the use of the derivatives and pharmaceutical compositions disclosed herein in treatment of obesity and various cancers.
    Type: Grant
    Filed: July 29, 2013
    Date of Patent: July 24, 2018
    Assignee: CITY OF HOPE
    Inventors: Samuel Rahbar, James L. Figarola, Christopher Lincoln, David Horne, Rachael Mooney, Monika Polewski, George Somlo, Lixin Yang, Sanjay Awasthi
  • Patent number: 9943530
    Abstract: Methods and compositions for treating 25-hydroxyvitamin D insufficiency and deficiency in a patient are described herein. The method includes orally administering to the patient a delayed, sustained release formulation including a first ingredient selected from the group consisting of 25-hydroxyvitamin D2, 25-hydroxyvitamin D3, or a combination of 25-hydroxyvitamin D2 and 25-hydroxyvitamin D3, or it includes gradually administering to the patient a sterile intravenous formulation including a first ingredient selected from the group consisting of 25-hydroxyvitamin D2, 25-hydroxyvitamin D3, or a combination of 25-hydroxyvitamin D2 and 25-hydroxyvitamin D3.
    Type: Grant
    Filed: November 19, 2014
    Date of Patent: April 17, 2018
    Assignee: OPKO RENAL, LLC
    Inventors: Charles W. Bishop, Keith H. Crawford, Eric J. Messner
  • Patent number: 9937146
    Abstract: A composition which includes Phenylalanine, Serine, Glutamine and GABA (?-aminobutyric acid). The composition contains the essential amino acids Phenylalanine; Glutamine; the non-essential amino acid Serine; and GABA (?-aminobutyric acid) in concentrations effective to influence or modulate the neurotransmitter pentapeptide enkephalin. The composition may further comprise tetrahydrocannabinol (THC).
    Type: Grant
    Filed: March 23, 2016
    Date of Patent: April 10, 2018
    Assignee: BIOADATP, LLC
    Inventor: Kevin Meehan
  • Patent number: 9918997
    Abstract: In one embodiment, the present application discloses methods of treating diseases and disorders with sulfasalazine and pharmaceutical formulations of sulfasalazine where the bioavailability of the sulfasalazine is increased. In another embodiment, the present application also provides dosing regimens for treating neurodegenerative diseases and disorders with compositions comprising sulfasalazine.
    Type: Grant
    Filed: February 10, 2017
    Date of Patent: March 20, 2018
    Assignee: GLIALOGIX, INC.
    Inventors: Thaddeus Cromwell Reeder, Mark Wade Moore, Douglas Alan Lorenz, David Keith Lyon
  • Patent number: 9913852
    Abstract: The method of treating elevated blood levels of iPTH by increasing or maintaining blood concentrations of both 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D in a patient by administering, as necessary, both Vitamin D repletion and Vitamin D hormone replacement therapies, is disclosed. The blood concentrations of 25-hydroxyvitamin D are increased to and maintained at or above 30 ng/mL, and blood concentrations of 1,25-dihydroxyvitamin D are increased to or maintained within a patient's normal historical physiological range for 1,25-dihydroxyvitamin D without causing substantially increased risk of hypercalcemia, hyperphosphatemia or over suppression of plasma iPTH in the patient. The blood levels of 25-hydroxyvitamin D are maintained at or above 30 ng/mL between doses of Vitamin D repletion therapies, and the blood levels of 1,25-dihydroxyvitamin D are maintained in the patient's normal historical physiological range between doses of Vitamin D hormone replacement therapies.
    Type: Grant
    Filed: July 27, 2016
    Date of Patent: March 13, 2018
    Assignees: OPKO IRELAND GLOBAL HODLINGS, LTD., OPKO RENAL, LLC
    Inventors: Charles W. Bishop, Keith H. Crawford, Eric J. Messner, P. Martin Petkovich, Christian F. Helvig
  • Patent number: 9901588
    Abstract: Doxycycline formulations with a reduced food effect are disclosed. Particularly disclosed are modified release formulations which can be administered once a day and exhibit a reduced food effect. Methods of treating inflammatory conductions such as rosacea or inflammatory symptoms such as the papules and pustules of rosacea or acne vulgaris are also disclosed.
    Type: Grant
    Filed: November 22, 2016
    Date of Patent: February 27, 2018
    Assignee: Nestlé Skin Health SA
    Inventors: Ankit Baheti, Bijay Kumar Padhi, Rajeev Singh Raghuvanshi
  • Patent number: 9889144
    Abstract: Pharmaceutical compositions, including unit dosage forms, comprising abiraterone acetate and methods for producing and using such compositions are described.
    Type: Grant
    Filed: July 10, 2017
    Date of Patent: February 13, 2018
    Assignee: iCeutica Inc.
    Inventors: Maura Murphy, Paul Nemeth, H. William Bosch, Matthew Callahan, Satya Bhamidipati, Jason Coleman, Christopher Hill, Marck Norret
  • Patent number: 9889152
    Abstract: Herein provided are dosage forms (variously referred to as “formulations”) comprising a PPI that is released from the dosage form as a first and a second dose. Each dose of PPI is present in an amount sufficient to raise the plasma levels of the PPI to at least 100 ng/ml.
    Type: Grant
    Filed: November 11, 2015
    Date of Patent: February 13, 2018
    Assignee: Takeda Pharmaceuticals U.S.A., Inc.
    Inventors: Rajneesh Taneja, Majid Vakilynejad
  • Patent number: 9889133
    Abstract: The disclosure provides an extended release formulation of 5-fluorocytosine. In another aspect, a method of treating a fungal disease is provided. The method comprises administering to a subject in need thereof a fungus-treating effective amount of a composition comprising 5-fluorocytosine. In yet another aspect, a method of treating a cancer is provided. The method comprises administering to a subject in need thereof a sufficient amount of an expression vector to induce expression of cytosine deaminase which is capable of converting 5-fluorocytosine to 5-fluorourcail in cells of the cancer and a cancer-treating effective amount of a composition comprising 5-fluorocytosine.
    Type: Grant
    Filed: April 22, 2016
    Date of Patent: February 13, 2018
    Assignee: Tocagen Inc.
    Inventors: Harry E. Gruber, Douglas J. Jolly, Kay Olmstead
  • Patent number: 9884054
    Abstract: Described herein are methods of treating non-metastatic castrate-resistant prostate cancer with anti-androgens.
    Type: Grant
    Filed: September 23, 2013
    Date of Patent: February 6, 2018
    Assignee: ARAGON PHARMACEUTICALS, INC.
    Inventor: Isan Chen
  • Patent number: 9879005
    Abstract: The present disclosure provides compositions and methods for treating ocular disorders in mammals especially in and not limited to humans and mice. The present disclosure further provides methods of treating cancer and appetite suppression using the compositions which are novel small molecule inhibitors of CaMKK2. In addition, these derived compositions can regulate non-ocular disorders, such as cancer and appetite suppression by modulating and inhibiting CaMKK2 and the regulation of the macrophage mediated diseases.
    Type: Grant
    Filed: February 5, 2016
    Date of Patent: January 30, 2018
    Assignee: Duke University
    Inventors: Scott W. Cousins, David M. Gooden, Priyatham S. Mettu
  • Patent number: 9867835
    Abstract: A method of treating or preventing a systemic viral infection in a mammal by administering a pharmaceutically acceptable composition selected from the group consisting of squalamine, an active isomer thereof, and an active analogue thereof, via a dosing regimen that delivers effective antiviral concentrations of squalamine. Also compositions for achieving the systemic antiviral effect.
    Type: Grant
    Filed: May 9, 2014
    Date of Patent: January 16, 2018
    Assignee: ENTERIN LABORATORIES, INC.
    Inventor: Michael Zasloff
  • Patent number: 9861649
    Abstract: The invention generally relates to methods to inhibit inflammation or pathogen infection by administering at least one anionic lipid or compositions comprising at least one anionic lipid to an individual. The invention also relates to methods to prevent or inhibit respiratory syncytial virus (RSV) infection by administering at least one anionic lipid or compositions comprising at least one anionic lipid to an individual. The invention further relates to compositions comprising randomly mixed surfactant lipids and methods to produce the compositions.
    Type: Grant
    Filed: June 27, 2014
    Date of Patent: January 9, 2018
    Assignee: National Jewish Health
    Inventor: Dennis R. Voelker
  • Patent number: 9856217
    Abstract: The present invention relates to crystalline forms of (1R,5S)-1-(naphthalen-2-yl)-3-azabicyclo[3.1.0]hexane hydrochloride and compositions comprising the same and methods of making and using the same.
    Type: Grant
    Filed: June 1, 2017
    Date of Patent: January 2, 2018
    Assignee: NEUROVANCE, INC.
    Inventors: Anthony Alexander McKinney, Franklin Bymaster, Walter Piskorski, Fred J. Fleitz, Yonglai Yang, David A. Engers, Valeriya Smolenskaya, Venkat Kusukuntla
  • Patent number: 9855277
    Abstract: The use of 5H-dibenz/b,f/azepine-5-carboxamide derivatives for treating fibromyalgia. Useful 5H-dibenz/b,f/azepine-5-carboxamide derivatives include compounds of the formula (I): where R1 is hydrogen, alkyl, halogenalkyl, aralkyl, cycloalkyl, cycloalkylalkyl, alkoxy, aryl, or pyridyl; the term alkyl means a straight or branched hydrocarbon chain containing from 1 to 18 carbon atoms; the term halogen means fluorine, chlorine, bromine or iodine; the term cycloalkyl means an alicyclic saturated group with 3 to 6 carbon atoms; and the term aryl means an unsubstituted phenyl group or phenyl substituted by alkoxy, halogen or nitro group.
    Type: Grant
    Filed: July 27, 2009
    Date of Patent: January 2, 2018
    Assignee: BIAL—PORTELA & CA, S.A.
    Inventor: Patricio Manuel Viera Araújo Soares Da Silva
  • Patent number: 9844535
    Abstract: Methods are disclosed herein for administering a oncogenic Src homology-2 domain containing protein tyrosine phosphatase-2 (SHP2) inhibitor for treating autoimmune and/or glomerulonephritis-associated diseases, and in particular, Systemic Lupus Erythematosus (SLE).
    Type: Grant
    Filed: July 2, 2014
    Date of Patent: December 19, 2017
    Assignee: Indiana University Research and Technology Corporation
    Inventors: Zhong-Yin Zhang, Maria Kontaridis, Li-Fan Zeng, Jianxun Wang
  • Patent number: 9840508
    Abstract: Novel compounds of Formula I and their use in therapeutic treatments.
    Type: Grant
    Filed: March 28, 2014
    Date of Patent: December 12, 2017
    Assignee: OGED SA
    Inventors: Hamid Hoveyda, Guillaume Dutheuil, Graeme Fraser
  • Patent number: 9828342
    Abstract: One aspect of the invention relates to novel isatin derivative compounds and the pharmaceutical composition thereof. Another aspect of the invention relates to methods of using the isatin derivative compounds disclosed herein and the pharmaceutical compositions thereof. In certain embodiments, the method is used to treat a cancer or a tumor in a subject including, without limitation, prostate cancer, melanoma, pancreatic cancer, ovarian cancer, and lymphoma. In certain embodiment, the method is used to treat a condition in a subject that can be regulated by the activation of one or more proteins such as EGFR, Erk1/2, Her2/Neu, Jak2, Src, Stat3, Akt, Cyclin B1, and Cdc25C. In certain embodiment, the method is used to treat a condition in a subject that can be regulated by the disruption of microtubule formations.
    Type: Grant
    Filed: February 25, 2013
    Date of Patent: November 28, 2017
    Assignees: CITY OF HOPE, THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: David A. Horne, Richard Jove, Christopher Lincoln, Sangkil Nam, Larry Overman, Jun Xie
  • Patent number: 9821008
    Abstract: Compositions and methods for inhibiting the DNA repair protein complex, ERCC1-XPF, and methods to enhance clinical responses to anticancer drugs that interact with DNA such as cisplatin, and to overcome drug resistance due to DNA repair mechanisms, are described.
    Type: Grant
    Filed: November 25, 2014
    Date of Patent: November 21, 2017
    Assignee: The University of Toledo
    Inventors: Stephan M. Patrick, Paul W. Erhardt, Christopher Trabbic
  • Patent number: 9822114
    Abstract: The invention relates to compounds of formula I wherein is a bond or is absent, V is CH, CR6 or N; R0 is H or, if is a bond, may also be alkoxy; R1 is H or halogen; U is CH or N when is a bond, or, if is absent, U is CH2, NH or NR9; R2 is H, alkylcarbonyl or —CH2—R3; R3 is H, alkyl or hydroxyalkyl; R4 is H or, if n is not 0 and R5 is H, may also be OH; R5 is H, alkyl, hydroxyalkyl, aminoalkyl, alkoxyalkyl, carboxy or alkoxycarbonyl; R6 is hydroxyalkyl, carboxy, alkoxycarbonyl or —(CH2)q—NR7R8, q being 1, 2 or 3 and each of R7 and R8 independently being H or alkyl or R7 and R8 forming with the N atom bearing them a ring; R9 is alkyl or hydroxyalkyl; A is —(CH2)p—, —CH2CH2CH(OH)— or —COCH2CH(OH)—; G is substituted phenyl or G1 or G2 wherein Q is O or S and X is CH or N; and Y1, Y2 and Y3 may each be CH or N; and n is 0 when A is —CH2CH2CH(OH)— or —COCH2CH(OH)—, and n is 0, 1 or 2 when A is —(CH2)p—, p being 1, 2, 3 or 4, with the proviso that the sum of n and p is then 2, 3 or 4; and to salts there
    Type: Grant
    Filed: April 21, 2016
    Date of Patent: November 21, 2017
    Assignee: IDORSIA PHARMACEUTICALS LTD
    Inventors: Christian Hubschwerlen, Daniel Ritz, Georg Rueedi, Jean-Philippe Surivet, Cornelia Zumbrunn-Acklin